Comparison of dual-biomarker PIB-PET and dual-tracer PET in AD diagnosis

European Radiology

Volumn 24, Issue 11, 2014, Pages 2800-2809

  Fu, Liping ^a   Liu, Linwen ^b   Zhang, Jinming ^a   Xu, Baixuan ^a   Fan, Yong ^b   Tian, Jiahe ^a  

^a The 302th Hospital of Chinese People s Liberation Army   (China)

^b INSTITUTE OF AUTOMATION   (China)

Author keywords

11C PIB; 18F FDG; Alzheimer s disease; A amyloid plaques; Mild cognitive impairment

Indexed keywords

BENZOTHIAZOLE DERIVATIVE; BIOLOGICAL MARKER; CARBON; FLUORODEOXYGLUCOSE F 18; N-METHYL-2-(4'-METHYLAMINOPHENYL)-6-HYDROXYBENZOTHIAZOLE; RADIOPHARMACEUTICAL AGENT;

AGED; ALZHEIMER DISEASE; COMPARATIVE STUDY; DIAGNOSTIC USE; FEMALE; HUMAN; MALE; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; REPRODUCIBILITY; SCINTISCANNING;

AGED; ALZHEIMER DISEASE; BENZOTHIAZOLES; BIOLOGICAL MARKERS; CARBON RADIOISOTOPES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS;

EID: 84930985951     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-014-3311-x     Document Type: Article

References (48)

1. Engler H, Forsberg A, Almkvist O et al (2006) Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 129:2856–2866
2. Kadir A, Almkvist O, Forsberg A et al (2012) Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease. Neurobiol Aging 33(198):e191–114
3. Bacskai BJ, Hickey GA, Skoch J et al (2003) Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci U S A 100:12462–12467
4. Ikonomovic MD, Klunk WE, Abrahamson EE et al (2008) Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 131:1630–1645
5. Klunk WE, Wang Y, Huang GF et al (2003) The binding of 2-(4'-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 23:2086–2092
6. Klunk WE, Engler H, Nordberg A et al (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 55:306–319
7. Mintun MA, Larossa GN, Sheline YI et al (2006) [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67:446–452
8. Rabinovici GD, Furst AJ, O'Neil JP et al (2007) 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 68:1205–1212
9. Gomperts SN, Rentz DM, Moran E et al (2008) Imaging amyloid deposition in Lewy body diseases. Neurology 71:903–910
10. Buongiorno M, Compta Y, Marti MJ (2011) Amyloid-beta and tau biomarkers in Parkinson’s disease-dementia. J Neurol Sci 310:25–30
11. Morris JC, Roe CM, Xiong C et al (2010) APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 67:122–131
12. Rowe CC, Ng S, Ackermann U et al (2007) Imaging beta-amyloid burden in aging and dementia. Neurology 68:1718–1725
13. Koeppe RA, Gilman S, Joshi A et al (2005) 11C-DTBZ and 18F-FDG PET measures in differentiating dementias. J Nucl Med 46:936–944
14. Van Laere K, Clerinx K, D'Hondt E, de Groot T, Vandenberghe W (2010) Combined striatal binding and cerebral influx analysis of dynamic 11C-raclopride PET improves early differentiation between multiple-system atrophy and Parkinson disease. J Nucl Med 51:588–595
15. Blomquist G, Engler H, Nordberg A et al (2008) Unidirectional Influx and Net Accumulation of PIB. Open Neuroimaging J 2:114–125
16. Price JC, Klunk WE, Lopresti BJ et al (2005) Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh compound-B. J Cereb Blood Flow Metab 25:1528–1547
17. Wu Y, Carson RE (2002) Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging. J Cereb Blood Flow Metab 22:1440–1452
18. Forsberg A, Engler H, Blomquist G, Langstrom B, Nordberg A (2012) The use of PIB-PET as a dual pathological and functional biomarker in AD. Biochim Biophys Acta 1822:380–385
19. Rostomian AH, Madison C, Rabinovici GD, Jagust WJ (2011) Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients. J Nucl Med 52:173–179
20. Yesavage JA, Brink TL, Rose TL et al (1982) Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 17:37–49
21. Morris JC (1993) The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43:2412–2414
22. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56:303–308
23. Albert MS, DeKosky ST, Dickson D et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7:270–279
24. McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7:263–269
25. Philippe C, Haeusler D, Mitterhauser M et al (2011) Optimization of the radiosynthesis of the Alzheimer tracer 2-(4-N-[11C] methylaminophenyl)-6-hydroxybenzothiazole ([11C]PIB). Appl Radiat Isot 69:1212–1217
26. Ashburner J (2007) A fast diffeomorphic image registration algorithm. Neuroimage 38:95–113
27. Tzourio-Mazoyer N, Landeau B, Papathanassiou D et al (2002) Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 15:273–289
28. Devanand DP, Mikhno A, Pelton GH et al (2010) Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls. J Geriatr Psychiatry Neurol 23:185–198
29. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE (1997) Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 42:85–94
30. Silverman DH, Small GW, Chang CY et al (2001) Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 286:2120–2127
31. Genovese CR, Lazar NA, Nichols T (2002) Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage 15:870–878
32. Mazziotta JC, Phelps ME (1986) Positron emission tomography studies of the brain. In: Phelps ME, Mazziotta JC, Schelbert H (eds) Positron emission tomography & autoradiography: principles & applications for the brain & heart. Raven, New York, pp 493–579
33. Mosconi L (2005) Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 32:486–510
34. Desgranges B, Baron JC, de la Sayette V et al (1998) The neural substrates of memory systems impairment in Alzheimer's disease. A PET study of resting brain glucose utilization. Brain 121(Pt 4):611–631
35. Haxby JV, Grady CL, Koss E et al (1990) Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. Arch Neurol 47:753–760
36. Sokoloff L (1981) Relationships among local functional activity, energy metabolism, and blood flow in the central nervous system. Fed Proc 40:2311–2316
37. Frackowiak RS, Pozzilli C, Legg NJ et al (1981) Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography. Brain 104:753–778
38. Nihashi T, Yatsuya H, Hayasaka K et al (2007) Direct comparison study between FDG-PET and IMP-SPECT for diagnosing Alzheimer's disease using 3D-SSP analysis in the same patients. Radiat Med 25:255–262
39. Rabinovici GD, Jagust WJ (2009) Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol 21:117–128
40. Fan Y, Batmanghelich N, Clark CM, Davatzikos C, Alzheimer's Disease Neuroimaging I (2008) Spatial patterns of brain atrophy in MCI patients, identified via high-dimensional pattern classification, predict subsequent cognitive decline. Neuroimage 39:1731–1743
41. Forsberg A, Engler H, Almkvist O et al (2008) PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 29:1456–1465
42. Kemppainen NM, Aalto S, Wilson IA et al (2007) PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 68:1603–1606
43. Lopresti BJ, Klunk WE, Mathis CA et al (2005) Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 46:1959–1972
44. Pike KE, Savage G, Villemagne VL et al (2007) Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 130:2837–2844
45. Mosconi L, Berti V, Glodzik L, Pupi A, De Santi S, de Leon MJ (2010) Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. J Alzheimers Dis 20:843–854
46. Jagust W (2009) Mapping brain beta-amyloid. Curr Opin Neurol 22:356–361
47. Jack CR Jr, Lowe VJ, Senjem ML et al (2008) 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 131:665–680
48. Jack CR Jr, Albert MS, Knopman DS et al (2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7:257–262